Cerulean Pharma

Making Nanoparticle-Drug Conjugates (NDCs) designed to target tumors, reduce toxicity, and enable combinations

placeCambridge, Massachusetts, United States calendar_todayFounded 2006 groups20 employees language ceruleanrx.com

Registered entities

Innovation

48 patent families (11 granted) — focus: Human necessities, Chemistry & metallurgy, Operations & transport, Physics & computing; filing pace slowing. Cited 9,869 times.

YearFilings
201219
201323
201428
201523
201616
20179
201811
20193
20203
20213

Investor mix

7 investors on record; lead investors include Bessemer Venture Partners, Lilly Ventures, Lux Capital, Polaris Partners.

Investor typeCountShare
Venture capital571%
Bank & private debt114%
Other / undisclosed114%
Coming soon